Viking Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Madrigal Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Protagonist Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Ascendis Pharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Revolution Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Blueprint Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A visual target evaluation report for PRKAB2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.

2026 Osteoarthritis Disease Modification clinical landscape covering trial endpoints, sponsors, phases, geographies, readouts, assets and development…

2026 Osteoporosis clinical landscape covering trial endpoints, sponsors, phases, geographies, readouts, assets and development white space.

2026 Maternal RSV Immunization clinical landscape covering trial endpoints, sponsors, phases, geographies, readouts, assets and development white space.

2026 Preterm Birth Prevention clinical landscape covering trial endpoints, sponsors, phases, geographies, readouts, assets and development white space.

2026 Preeclampsia Prevention clinical landscape covering trial endpoints, sponsors, phases, geographies, readouts, assets and development white space.